Abstract 739P
Background
Penile squamous cell carcinoma (PSCC) is rare and the immune enviroment of PSCC remains poorly characterized. In this study, we characterize the immune microenvironment using multiplex immunofluorescence (mIF) and image analysis approaches in 57 patients with PSCC.
Methods
Representative tissue microarrays blocks of 57 patients with primary PSCC treated at H. Lee Moffitt Cancer Center (Tampa, FL) were stained for 10 immune markers: CD20, CD3, CD4, CD8, CD45RO, CD68, CD206, CD163, NKp46, FOXP3. Two experienced pathologists using an image analysis system divided each tissue core into tumor and stroma compartments and assessed the densities of cell phenotypes.For analyses focusing on overall survival (OS) we used Cox regression and Log-rank test for Kaplan-Meier plots. The maximally selected rank statistics test was used to identify cut-points of continuous variables with maximal discriminatory value for clinical outcomes.
Results
57 PSCC patients were included with median age 60 [IQR, 53-73]). 25 (44%) were pathologic stages 1-2, 25 (44%) were stage 3, and 7 (12%) were stage 4. 34 (60%) were HPV-negative. We did not observe significant differences in cell densities as defined by mIF in HPV(+) compared to HPV(–) PSCC. In univariable analysis, higher density of CD8+ cells in the tumor and stroma were associated with inferior median OS (36.6 months [95% CI, 19.0-84.1] vs 161.7 months [95% CI, 16.2-161.7]). Similarly, greater infiltration by tumor-associated (M2) macrophages in the tumor and stroma (CD68+CD163+CD206+) were associated with inferior median OS (13.3 months [95% CI, 1.0-not estimable) vs 80.1 months [95% CI, 27.1-161.2]. In Cox regression controlling for pathologic stage and M2 density as a continuous variable, the latter remained significantly associated with OS.
Conclusions
Multiplex image analysis of primary PSCC found no difference in the immune contexture of HPV(+) and HPV(-) patients. High levels of tumor-associated macrophages M2 was associated with inferior survival outcomes. Further characterization of T-cell subsets to gauge the exhausted status of T-cells is underway to explain the paradoxical effect noted, similar to that in kidney cancer immune environment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Chahoud.
Funding
Has not received any funding.
Disclosure
S. Eschrich: Financial Interests, Personal, Member of Board of Directors: Cvergenx. P. Spiess: Non-Financial Interests, Institutional, Trial Chair: NCCN; Non-Financial Interests, Institutional, Speaker, Consultant, Advisor: ASCO/EAU; Non-Financial Interests, Personal and Institutional, Ownership Interest: Global Society of Rare GU Tumors. All other authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18